FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964365162> ?p ?o ?g. }

• W2964365162 endingPage "601" @default.
• W2964365162 startingPage "595" @default.
• W2964365162 abstract "The B-cell receptor and the phosphatidylinositol 3-kinase (PI3K) signalling pathways, together with their downstream partners, represent important therapeutic targets for B-cell lymphomas. Here, we evaluated the activity of acalabrutinib (ACP-196) and ACP-319 (AMG-319), second generation inhibitors of Bruton tyrosine kinase (BTK) and PI3Kδ inhibitor, respectively, in lymphoma pre-clinical models. The two compounds showed activity in activated B-cell-like diffuse large B-cell lymphoma (ABC DLBCL), mantle cell lymphoma and marginal zone lymphoma. Two in vivo experiments with ABC DLBCL and MCL xenografts confirmed the effect of the single agents. Benefit was achieved by exposing the lymphoma cell lines to both acalabrutinib and ACP-319. Two cell lines presented a discordant response to first and second generation BTK inhibitors, probably due to the inhibition by ibrutinib of kinases other than BTK. In conclusion, our data sustain the on-going current trials with acalabrutinib and ACP-319 as single agents and provide the basis for the investigation of their combination as well." @default.
• W2964365162 created "2019-08-13" @default.
• W2964365162 creator A5009234092 @default.
• W2964365162 creator A5012537023 @default.
• W2964365162 creator A5025143746 @default.
• W2964365162 creator A5031130648 @default.
• W2964365162 creator A5038420682 @default.
• W2964365162 creator A5048622832 @default.
• W2964365162 creator A5054086723 @default.
• W2964365162 creator A5059963876 @default.
• W2964365162 creator A5064713685 @default.
• W2964365162 creator A5065466882 @default.
• W2964365162 creator A5066518317 @default.
• W2964365162 creator A5077930649 @default.
• W2964365162 creator A5091441095 @default.
• W2964365162 date "2019-07-29" @default.
• W2964365162 modified "2023-10-14" @default.
• W2964365162 title "Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP‐319 in pre‐clinical models of aggressive lymphomas" @default.
• W2964365162 cites W1020989877 @default.
• W2964365162 cites W1199719327 @default.
• W2964365162 cites W1625383933 @default.
• W2964365162 cites W1908764360 @default.
• W2964365162 cites W2049165837 @default.
• W2964365162 cites W2052787205 @default.
• W2964365162 cites W2053391598 @default.
• W2964365162 cites W2067257663 @default.
• W2964365162 cites W2079012552 @default.
• W2964365162 cites W2109367246 @default.
• W2964365162 cites W2159171427 @default.
• W2964365162 cites W2316021978 @default.
• W2964365162 cites W2497974852 @default.
• W2964365162 cites W2558640761 @default.
• W2964365162 cites W2561449166 @default.
• W2964365162 cites W2571275916 @default.
• W2964365162 cites W2577842801 @default.
• W2964365162 cites W2586070543 @default.
• W2964365162 cites W2587684973 @default.
• W2964365162 cites W2665803427 @default.
• W2964365162 cites W2705118184 @default.
• W2964365162 cites W2741676078 @default.
• W2964365162 cites W2743273314 @default.
• W2964365162 cites W2745694502 @default.
• W2964365162 cites W2750906538 @default.
• W2964365162 cites W2765262832 @default.
• W2964365162 cites W2774438734 @default.
• W2964365162 cites W2774522106 @default.
• W2964365162 cites W2885662967 @default.
• W2964365162 cites W2891564385 @default.
• W2964365162 cites W2903942209 @default.
• W2964365162 cites W2911611311 @default.
• W2964365162 cites W2951749653 @default.
• W2964365162 cites W2980054803 @default.
• W2964365162 doi "https://doi.org/10.1111/bjh.16118" @default.
• W2964365162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31355927" @default.
• W2964365162 hasPublicationYear "2019" @default.
• W2964365162 type Work @default.
• W2964365162 sameAs 2964365162 @default.
• W2964365162 citedByCount "11" @default.
• W2964365162 countsByYear W29643651622020 @default.
• W2964365162 countsByYear W29643651622021 @default.
• W2964365162 countsByYear W29643651622022 @default.
• W2964365162 countsByYear W29643651622023 @default.
• W2964365162 crossrefType "journal-article" @default.
• W2964365162 hasAuthorship W2964365162A5009234092 @default.
• W2964365162 hasAuthorship W2964365162A5012537023 @default.
• W2964365162 hasAuthorship W2964365162A5025143746 @default.
• W2964365162 hasAuthorship W2964365162A5031130648 @default.
• W2964365162 hasAuthorship W2964365162A5038420682 @default.
• W2964365162 hasAuthorship W2964365162A5048622832 @default.
• W2964365162 hasAuthorship W2964365162A5054086723 @default.
• W2964365162 hasAuthorship W2964365162A5059963876 @default.
• W2964365162 hasAuthorship W2964365162A5064713685 @default.
• W2964365162 hasAuthorship W2964365162A5065466882 @default.
• W2964365162 hasAuthorship W2964365162A5066518317 @default.
• W2964365162 hasAuthorship W2964365162A5077930649 @default.
• W2964365162 hasAuthorship W2964365162A5091441095 @default.
• W2964365162 hasBestOaLocation W29643651621 @default.
• W2964365162 hasConcept C126322002 @default.
• W2964365162 hasConcept C170493617 @default.
• W2964365162 hasConcept C185592680 @default.
• W2964365162 hasConcept C203014093 @default.
• W2964365162 hasConcept C2777525834 @default.
• W2964365162 hasConcept C2777938653 @default.
• W2964365162 hasConcept C2778461978 @default.
• W2964365162 hasConcept C2779338263 @default.
• W2964365162 hasConcept C2779878957 @default.
• W2964365162 hasConcept C42362537 @default.
• W2964365162 hasConcept C502942594 @default.
• W2964365162 hasConcept C55493867 @default.
• W2964365162 hasConcept C62478195 @default.
• W2964365162 hasConcept C71924100 @default.
• W2964365162 hasConcept C86554907 @default.
• W2964365162 hasConcept C90059517 @default.
• W2964365162 hasConcept C98274493 @default.
• W2964365162 hasConceptScore W2964365162C126322002 @default.
• W2964365162 hasConceptScore W2964365162C170493617 @default.
• W2964365162 hasConceptScore W2964365162C185592680 @default.
• W2964365162 hasConceptScore W2964365162C203014093 @default.

• next